Clinipace Acquisition Pan-Asia CRO, Choice Pharma - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Clinipace Acquisition Pan-Asia CRO, Choice Pharma

Source: Applied Clinical Trials

Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.

The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements

There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.

This is the 5th acquisition by Clinipace in recent years.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here